Blennow K - Search Results

1

Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.

Falgàs N, Ruiz-Peris M, Pérez-Millan A, Sala-Llonch R, Antonell A, Balasa M, Borrego-Écija S, Ramos-Campoy O, Augé JM, Castellví M, Tort-Merino A, Olives J, Fernández-Villullas G, Blennow K, Zetterberg H, Bargalló N, Lladó A, Sánchez-Valle R. Falgàs N, et al. Among authors: blennow k. Hum Brain Mapp. 2020 Jun 1;41(8):2004-2013. doi: 10.1002/hbm.24925. Epub 2020 Jan 16. Hum Brain Mapp. 2020. PMID: 31944489 Free PMC article.

2

Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.

Blennow K, Wallin A, Gottfries CG, Lekman A, Karlsson I, Skoog I, Svennerholm L. Blennow K, et al. Neurobiol Aging. 1992 Jan-Feb;13(1):107-13. doi: 10.1016/0197-4580(92)90017-r. Neurobiol Aging. 1992. PMID: 1371850

3

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blennow K, et al. Acta Neurol Scand. 1990 Apr;81(4):323-6. doi: 10.1111/j.1600-0404.1990.tb01563.x. Acta Neurol Scand. 1990. PMID: 2360400

4

White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia--diagnostic and pathogenetic aspects.

Wallin A, Blennow K, Uhlemann C, Långström G, Gottfries CG. Wallin A, et al. Among authors: blennow k. Acta Neurol Scand. 1989 Dec;80(6):518-23. doi: 10.1111/j.1600-0404.1989.tb03920.x. Acta Neurol Scand. 1989. PMID: 2618578

5

Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.

Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Blennow K, et al. Int Psychogeriatr. 1994 Spring;6(1):13-22; discussion 59-60. doi: 10.1017/s1041610294001584. Int Psychogeriatr. 1994. PMID: 8054491

6

Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform.

Landén M, Hesse C, Fredman P, Regland B, Wallin A, Blennow K. Landén M, et al. Among authors: blennow k. Dementia. 1996 Sep-Oct;7(5):273-8. doi: 10.1159/000106892. Dementia. 1996. PMID: 8872419

7

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.

Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Sjögren M, et al. Among authors: blennow k. Neurobiol Aging. 1998 Sep-Oct;19(5):379-84. doi: 10.1016/s0197-4580(98)00086-4. Neurobiol Aging. 1998. PMID: 9880039

8

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.

Sjögren M, Minthon L, Davidsson P, Granérus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. Sjögren M, et al. Among authors: blennow k. J Neural Transm (Vienna). 2000;107(5):563-79. doi: 10.1007/s007020070079. J Neural Transm (Vienna). 2000. PMID: 11072752

9

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H. Blennow K, et al. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. doi: 10.1385/MN:24:1-3:087. Mol Neurobiol. 2001. PMID: 11831556 Review.

10

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,211 results

Search Page

Filters